Paris, France — 13 April 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…
Paris, France — 25 January 2021 at 08:00am — Lysogene (FR0013233475 – LYS), a phase…
Paris, France — 15 January 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…
LYS-GM101 is Lysogene’s second CNS gene therapy program to enter clinicTrial enrollment expected to begin…
Decrease in heparan sulfate concentration in cerebrospinal fluidDecrease in GM2 and GM3 ganglioside in cerebrospinal…
Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021
Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on…
Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations…
Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held…
Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase…